MAM
DD gets board clearance to initiate steps for legal action against TAM
NEW DELHI: TAM Media, the sole television ratings agency in India, is now under attack from the pubcaster. The Prasar Bharati board Monday formally gave approval to Doordarshan to finalise the parameters of legal action against TAM for generally overlooking the ratings of the state-owned network which has the largest reach in the country.
Prasar Bharati chief executive officer Jawahar Sircar told indiantelevision.com that the board took cognizance of the grievances of Doordarshan in this regard.
The board was apprised of the discussions held so far with the legal experts. The board would approach the Information and Broadcasting Ministry after getting the legal opinion.
Doordarshan has the largest reach terrestrially through local cable operators and around 20 per cent of the market through various DTH platforms.
The action by Prasar Bharati comes close on the heels of the case filed by NDTV in a New York court against The Nielsen Co, a global research and information firm, and Kantar Media Research, the owners of TAM Media. NDTV has sought $810 million as compensation for the loss in revenues it has suffered over the years and $580 million in penalty for negligence by Nielsen and Kantar officials.
Doordarshan with a reach of 92 per cent in the country through 1415 transmitters has a terrestrial reach to around 25 million viewers, apart from those getting the feed through the DTH and other platforms. In fact, Sircar claimed that DD Direct Plus is reaching out to another ten million viewers, thus taking the direct reach to 35 million.
Also read:
Agencies feel need to speed up BARC
NDTV lawsuit may trigger Govt action on BARC
NDTV sues TAM, Nielsen for manipulation of data
NDTV lawsuit: Govt may investigate TAM
The ball is in the IBF court: AAAI prez Arvind Sharma
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
